Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
It’s shaping up to be an expensive few years for Johnson & Johnson.
On Oct. 9, a Philadelphia judge ordered the pharmaceutical and CPG behemoth to pay $8 billion to 26-year-old Nicholas Murray, who claimed that Risperdal, an anti-psychotic drug manufactured by J&J’s pharmaceutical subsidiary Janssen, made him grow breasts.
Murray’s lawyers claimed Johnson & Johnson did not properly warn that breast growth could be a side effect of the drug, and argued the company put “profits over patients” in marketing Risperdal.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in